Bolt Biotherapeutics Reports Decrease in Revenue and Operating Losses for Q1 2026

Bolt Biotherapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a significant decrease in revenue and a continued trend of operating losses. The company generated collaboration revenue of $26,000 for the three months ended March 31, 2026, a sharp decline from $1.2 million in the same period last year. This decrease is attributed to limited activities with collaboration partners, as the company continues to focus on its research and development efforts. Operating expenses also fell to $7.6 million from $13.3 million year-over-year, primarily due to reduced research and development costs following a workforce reduction in late 2025.

The company’s net loss for the first quarter of 2026 was $7.2 million, an improvement compared to the $11.0 million loss reported in the first quarter of 2025. This reduction in losses is largely due to decreased operating expenses, particularly in research and development, which dropped from $9.5 million to $4.8 million. General and administrative expenses also decreased from $3.8 million to $2.8 million, reflecting the impact of the workforce reduction that cut approximately 50% of the company's staff.

As of March 31, 2026, Bolt Biotherapeutics reported total assets of $48.0 million, down from $56.7 million at the end of 2025. The decline in assets is primarily due to a decrease in cash and short-term investments. The company had cash and cash equivalents of $11.6 million, alongside short-term investments of $11.3 million. The accumulated deficit increased to $468.0 million, raising concerns about the company's ability to continue as a going concern within the next year without additional capital.

In terms of operational developments, Bolt Biotherapeutics is advancing its clinical programs, including the ongoing Phase 1/2 trial of its lead candidate, BDC-4182, which targets the tumor-associated antigen claudin 18.2. The company is also engaged in collaborations with Toray Industries and Genmab, which are expected to contribute to its pipeline of immune-stimulating antibody conjugates. However, the company has indicated that it will need to raise additional capital to fund its operations and continue its development programs, as it anticipates ongoing net losses and negative cash flows.

Looking ahead, Bolt Biotherapeutics faces significant challenges in securing the necessary funding to support its clinical trials and operational expenses. The company has expressed substantial doubt about its ability to continue as a going concern within one year from the issuance of its financial statements, emphasizing the need for strategic partnerships or financing to sustain its operations and advance its product candidates.